CA2742922C - Pyrazolone-derivatives and their use as pd4 inhibitors - Google Patents

Pyrazolone-derivatives and their use as pd4 inhibitors Download PDF

Info

Publication number
CA2742922C
CA2742922C CA2742922A CA2742922A CA2742922C CA 2742922 C CA2742922 C CA 2742922C CA 2742922 A CA2742922 A CA 2742922A CA 2742922 A CA2742922 A CA 2742922A CA 2742922 C CA2742922 C CA 2742922C
Authority
CA
Canada
Prior art keywords
dihydro
piperidin
pyrazol
dimethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2742922A
Other languages
English (en)
French (fr)
Other versions
CA2742922A1 (en
Inventor
Imre Schlemminger
Beate Schmidt
Dieter Flockerzi
Hermann Tenor
Christof Zitt
Armin Hatzelmann
Degenhard Marx
Clemens Braun
Raimund Kuelzer
Anke Heuser
Hans-Peter Kley
Geert Jan Sterk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Takeda GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2742922(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda GmbH filed Critical Takeda GmbH
Publication of CA2742922A1 publication Critical patent/CA2742922A1/en
Application granted granted Critical
Publication of CA2742922C publication Critical patent/CA2742922C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2742922A 2008-11-14 2009-11-12 Pyrazolone-derivatives and their use as pd4 inhibitors Expired - Fee Related CA2742922C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08169143.8 2008-11-14
EP08169143 2008-11-14
US19333308P 2008-11-19 2008-11-19
US61/193,333 2008-11-19
PCT/EP2009/065031 WO2010055083A1 (en) 2008-11-14 2009-11-12 Novel pyrazolone-derivatives and their use as pd4 inhibitors

Publications (2)

Publication Number Publication Date
CA2742922A1 CA2742922A1 (en) 2010-05-20
CA2742922C true CA2742922C (en) 2018-02-27

Family

ID=40427227

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2742922A Expired - Fee Related CA2742922C (en) 2008-11-14 2009-11-12 Pyrazolone-derivatives and their use as pd4 inhibitors

Country Status (26)

Country Link
US (2) US8609848B2 (ja)
EP (1) EP2356103B1 (ja)
JP (1) JP5599405B2 (ja)
KR (1) KR20110082616A (ja)
CN (1) CN102369194B (ja)
AR (1) AR074318A1 (ja)
AU (1) AU2009315615A1 (ja)
BR (1) BRPI0921335A8 (ja)
CA (1) CA2742922C (ja)
CO (1) CO6331469A2 (ja)
EA (1) EA018585B1 (ja)
EC (1) ECSP11011034A (ja)
ES (1) ES2553754T3 (ja)
GE (1) GEP20135918B (ja)
HK (1) HK1167406A1 (ja)
IL (1) IL212700A0 (ja)
MA (1) MA32885B1 (ja)
ME (1) ME01134B (ja)
MX (1) MX2011005030A (ja)
MY (1) MY154019A (ja)
NZ (1) NZ593262A (ja)
PE (1) PE20110539A1 (ja)
TW (1) TWI460172B (ja)
UA (1) UA105910C2 (ja)
WO (1) WO2010055083A1 (ja)
ZA (1) ZA201102028B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074318A1 (es) * 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
WO2014090990A1 (en) * 2012-12-13 2014-06-19 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2903460A (en) * 1956-04-07 1959-09-08 Sandoz Ag Pyrazolone derivatives
US4550119A (en) 1983-05-23 1985-10-29 Warner-Lambert Company 2,4-Dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones
PT971901E (pt) 1997-01-15 2003-07-31 Altana Pharma Ag Ftalazinonas
KR20030074817A (ko) * 2001-02-15 2003-09-19 알타나 파마 아게 Ｐｄｅ4 억제제로서의 프탈라지논-피페리디노-유도체
NZ529221A (en) 2001-04-25 2005-04-29 Altana Pharma Ag Phthalazinones with PDE-inhibiting properties for treatment of airway disorders and other inflammatory conditions
AU2003255376A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
EP1537100B1 (en) * 2002-08-10 2007-04-25 ALTANA Pharma AG Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
PL373146A1 (en) 2002-08-10 2005-08-22 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
EP1720854A1 (en) 2004-02-04 2006-11-15 Altana Pharma AG Phthalzinone derivatives as pde4 inhibitors
JP4778449B2 (ja) * 2004-02-04 2011-09-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての２−（ピペリジン−４−イル）−４，５−ジヒドロ−２ｈ−ピリダジン−３−オン誘導体
CN104803973A (zh) * 2004-03-03 2015-07-29 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
CA2565599C (en) 2004-05-18 2012-07-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
AU2007212429A1 (en) * 2006-02-07 2007-08-16 Wyeth 11-beta HSD1 inhibitors
MY154498A (en) * 2007-05-16 2015-06-30 Takeda Gmbh Pyrazolone derivatives as pde4 inhibitors
CA2692249A1 (en) * 2007-06-19 2008-12-24 Yasushi Kohno Pyrazolone derivative and pde inhibitor containing the same as active ingredient
AR074318A1 (es) * 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.

Also Published As

Publication number Publication date
US20110218201A1 (en) 2011-09-08
CA2742922A1 (en) 2010-05-20
AU2009315615A1 (en) 2011-06-30
EA201100740A1 (ru) 2012-01-30
IL212700A0 (en) 2011-07-31
EP2356103A1 (en) 2011-08-17
US9340522B2 (en) 2016-05-17
US20140073672A1 (en) 2014-03-13
ES2553754T3 (es) 2015-12-11
TW201022228A (en) 2010-06-16
MA32885B1 (fr) 2011-12-01
EP2356103B1 (en) 2015-08-26
ECSP11011034A (es) 2011-06-30
CN102369194A (zh) 2012-03-07
JP2012508720A (ja) 2012-04-12
CO6331469A2 (es) 2011-10-20
NZ593262A (en) 2013-03-28
WO2010055083A1 (en) 2010-05-20
HK1167406A1 (en) 2012-11-30
KR20110082616A (ko) 2011-07-19
BRPI0921335A8 (pt) 2017-12-05
PE20110539A1 (es) 2011-08-04
UA105910C2 (uk) 2014-07-10
CN102369194B (zh) 2014-08-27
JP5599405B2 (ja) 2014-10-01
GEP20135918B (en) 2013-09-10
ZA201102028B (en) 2011-11-30
TWI460172B (zh) 2014-11-11
AR074318A1 (es) 2011-01-05
MX2011005030A (es) 2011-05-30
ME01134B (me) 2013-03-20
US8609848B2 (en) 2013-12-17
EA018585B1 (ru) 2013-09-30
MY154019A (en) 2015-04-30
BRPI0921335A2 (pt) 2017-06-06

Similar Documents

Publication Publication Date Title
US9090597B2 (en) Pyrazolone derivatives as PDE4 inhibitors
US9340522B2 (en) Pyrazolone-derivatives and their use as PDE-4 inhibitors
JP2007520528A (ja) Ｐｄｅ４インヒビターとしての２−（ピペリジン−４−イル）−４，５−ジヒドロ−２ｈ−ピリダジン−３−オン誘導体
LI et al. PYRAZOLONDERIVATE ALS PDE4-INHIBITOREN DERIVES DE PYRAZOLONE EN TANT QU’INHIBITEURS DE LA PDE4

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141014

MKLA Lapsed

Effective date: 20191112